高血压患者接受多沙唑嗪、复方阿米洛利和氨氯地平交叉治疗期间血脂和脂蛋白值的变化。

Changes in lipid and lipoprotein values during a cross-over treatment of doxazosin, moduretic and amlodipine in hypertensive patients.

作者信息

Ahaneku J E, Taylor G O, Agbedana E O, Walker O, Salako L A

机构信息

Department of Biochemistry and Cell Biology, National Institute of Health, Tokyo, Japan.

出版信息

J Pak Med Assoc. 1994 Jul;44(7):166-9.

PMID:7933456

Abstract

A cross-over study, comparing the effects of doxazosin, moduretic and amlodipine on plasma lipid and lipoprotein levels in 9 hypertensive Nigerians aged 35 to 65 years is presented. Doxazosin therapy had favourable lipid changes characterized by a statistically significant reduction in total cholesterol (TC) at 6 months. Though consistent reduction was observed in total triglycerides (TG) low density lipoprotein cholesterol (LDL-C), very low density lipoprotein-cholesterol (VLDLC) upto 6 months, no effect was seen on high density lipoprotein cholesterol (HDLC). This is against unfavourable increments in the mean values of TC, VLDLC, LDLC/HDLC and decrease in HDLC/TC during moduretic treatment phase. Amlodipine therapy did not alter the lipid and lipoprotein levels. The non-significant variation in the mean high density lipoprotein-cholesterol (HDLC) level observed with these agents, seem to suggest that HDL-cholesterol metabolism may be maintained during antihypertensive pharmacotherapy.

摘要

本文介绍了一项交叉研究，该研究比较了多沙唑嗪、莫得利克（一种复方制剂，含氢氯噻嗪和氨苯蝶啶）和氨氯地平对9名年龄在35至65岁的尼日利亚高血压患者血浆脂质和脂蛋白水平的影响。多沙唑嗪治疗引起了有利的脂质变化，其特征是在6个月时总胆固醇（TC）有统计学意义的降低。虽然在6个月内观察到总甘油三酯（TG）、低密度脂蛋白胆固醇（LDL-C）、极低密度脂蛋白胆固醇（VLDLC）持续降低，但对高密度脂蛋白胆固醇（HDLC）没有影响。这与莫得利克治疗阶段TC、VLDLC、LDL-C/HDLC平均值的不利增加以及HDLC/TC的降低形成对比。氨氯地平治疗未改变脂质和脂蛋白水平。这些药物观察到的平均高密度脂蛋白胆固醇（HDLC）水平无显著变化，似乎表明在抗高血压药物治疗期间HDL胆固醇代谢可能得以维持。